Biogen, Inc. (BIIB)
248.93
-0.08
(-0.03%)
USD |
NASDAQ |
Nov 03, 16:00
248.44
-0.49
(-0.20%)
After-Hours: 06:25
Biogen Free Cash Flow : 1.644B for Sept. 30, 2026
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| September 30, 2026 | 1.644B |
| June 30, 2026 | 2.49B |
| March 31, 2026 | 2.316B |
| December 31, 2025 | 1.969B |
| September 30, 2025 | 2.262B |
| June 30, 2025 | 1.847B |
| March 31, 2025 | 2.296B |
| December 31, 2024 | 2.516B |
| September 30, 2024 | 1.768B |
| June 30, 2024 | 1.468B |
| March 31, 2024 | 1.284B |
| December 31, 2023 | 1.236B |
| September 30, 2023 | 1.026B |
| June 30, 2023 | 1.123B |
| March 31, 2023 | 1.421B |
| December 31, 2022 | 1.141B |
| September 30, 2022 | 2.173B |
| June 30, 2022 | 2.315B |
| March 31, 2022 | 2.772B |
| December 31, 2021 | 3.345B |
| September 30, 2021 | 2.107B |
| June 30, 2021 | 2.461B |
| March 31, 2021 | 3.149B |
| December 31, 2020 | 3.678B |
| September 30, 2020 | 5.841B |
| Date | Value |
|---|---|
| June 30, 2020 | 6.349B |
| March 31, 2020 | 6.282B |
| December 31, 2019 | 6.409B |
| September 30, 2019 | 6.384B |
| June 30, 2019 | 6.324B |
| March 31, 2019 | 5.382B |
| December 31, 2018 | 5.302B |
| September 30, 2018 | 4.975B |
| June 30, 2018 | 4.779B |
| March 31, 2018 | 4.791B |
| December 31, 2017 | 2.708B |
| September 30, 2017 | 2.759B |
| June 30, 2017 | 2.226B |
| March 31, 2017 | 2.239B |
| December 31, 2016 | 3.929B |
| September 30, 2016 | 3.390B |
| June 30, 2016 | 3.240B |
| March 31, 2016 | 3.298B |
| December 31, 2015 | 3.073B |
| September 30, 2015 | 3.045B |
| June 30, 2015 | 3.230B |
| March 31, 2015 | 3.239B |
| December 31, 2014 | 2.654B |
| September 30, 2014 | 2.619B |
| June 30, 2014 | 2.359B |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.21B |
| Gilead Sciences, Inc. | 13.78B |
| Amgen, Inc. | 10.18B |
| Eli Lilly & Co. | 11.69B |
| Regeneron Pharmaceuticals, Inc. | 3.628B |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 640.80M |
| Cash from Investing (Quarterly) | -222.10M |
| Cash from Financing (Quarterly) | -393.80M |
| Free Cash Flow Per Share (Quarterly) | 2.540 |
| Free Cash Flow to Equity (Quarterly) | 929.20M |
| Free Cash Flow to Firm (Quarterly) | 575.68M |
| Free Cash Flow Yield | 4.47% |